 
BurstDR™ micrOdosing stimuLation in De -novo patients  
 
 
  
[STUDY_ID_REMOVED]  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534941]™ micrOdosing stimuLation in De- novo patients  
CRD_ 924 
Study Document No: < SJM- CIP-No> 
Version [ A] 
Date: 05-19-2017  
Clinical Investigation Plan (CIP) 
 
 Sponsor    Abbott  
           [ADDRESS_534942]  
          Plano, TX [ZIP_CODE]  
           [LOCATION_003] 
 Coordinating    Name/Title  
Investigator                             Hospi[INVESTIGATOR_423577]/function  
          Address  
           City 
           Country  
   
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534943] read and agree to adhere to the clinical investigation plan and all regulatory requirements 
applicable in conducting this clinical investigation . 
  Principal Investigator  
 
[INVESTIGATOR_115653]:  
Signature:  
[CONTACT_1782]:  
 
       
 
             
 
 
         
   
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 3 of 41 
 
Coordinating Investigator/ National Investigator  
 
SIGNATURE [CONTACT_1783]  
 
I have read and agree to adhere to the clinical investigation plan and all regulatory requirements 
applicable i n conducting this clinical investigation .  
  Coordinating Investigator/  National Investigator    
 
Printed name:  
[INVESTIGATOR_7496]:  
Date:  
 
    
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 4 of 41 
 
Table of Contents  
 
1 Synopsis  ................................................................................................................................................. 8 
 Objective(s)  ................................................................................................................................... 8 
 Devices Used  ................................................................................................................................ 8 
 Indications for Use ........................................................................ Error! Bookmark not defined.  
 Design  ........................................................................................................................................... 9 
 Endpoints  ..................................................................................................................................... 11 
1.5.1  Primary Endpoints  ................................................................................................................... 11 
1.5.2  Secondary Endpoints  .............................................................................................................. 11 
1.5.3  Descriptive Endpoint(s), if applicable  ...................................................................................... 11 
 Study Population  ......................................................................................................................... 11 
 Inclusion/Exclusion Criteria  ......................................................................................................... 11 
1.7.1  Inclusion Criteria  ...................................................................................................................... 11 
1.7.2  Exclusion Criteria  ..................................................................................................................... 12 
 Enrollment  ................................................................................................................................... 12 
 Study Assessments  ..................................................................................................................... 12 
 Study Flow Chart, if applicable  ..................................................... Error! Bookmark not defined.  
2 Introduction ........................................................................................................................................... 12 
3 Background and Justification for Clinical Investigation  ........................................................................ 13 
4 Device(s) Under Investigation  .............................................................................................................. 14 
 Identification and Description of the Devices under investigation  ............................................... 14 
4.1.1  Identification  ............................................................................................................................ 14 
4.1.2  Device Description and Intended Purpose  .............................................................................. 14 
4.1.3  Intended Purpose within the Clinical Investigation, if different  . Error! Bookmark not defined.  
4.1.4  Device Handling and Storage  .................................................................................................. 15 
 Description of  Comparator Device, if applicable  .......................... Error! Bookmark not defined.  
4.2.1  Identification  ............................................................................................................................ 15 
4.2.2  Comparator Description and Intended Purpose  ....................... Error! Bookmark not defined.  
4.2.3  Justification of Choice of Comparators ..................................... Error! Bookmark not defined.  
4.2.4  Device Handling and Storage  ................................................... Error! Bookmark not defined.  
 Devices Accountability, if applicable  ........................................................................................... 15 
5 Clinical Investigation Design  ................................................................................................................ 15 
 Clinical Investigation Design  ....................................................................................................... 15 
 Objectives  .................................................................................................................................... 17 
5.2.1  Primary Objectives  .................................................................................................................. 17 
5.2.2 Secondary Objectives .............................................................................................................. 17 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 5 of 41 
 
 Endpoints  ..................................................................................................................................... 17 
5.3.1  Primary Endpoint  ..................................................................................................................... 17 
5.3.2  Secondary Endpoint  ................................................................................................................ 17 
5.3.3 Descriptive Endpoint(s)  ........................................................................................................... 18 
 Study Population  ......................................................................................................................... 18 
5.4.1  Inclusion Criteria  ...................................................................................................................... 18 
5.4.2 Exclusion Criteria  ..................................................................................................................... 18 
5.4.3  Enrollment of Medicare Beneficiaries, if applicable  .................. Error! Bookmark not defined.  
5.4.4  Historically Underrepresented Demographic Subgroups, if applicable  ... Error! Bookmark not 
defined.  
6 Procedures  ........................................................................................................................................... 19 
 Patient Recr uitment, if applicable  ................................................. Error! Bookmark not defined.  
 Informed Consent Process  .......................................................................................................... 20 
6.2.1  Special circumstances for informed consent, if applicable  ....... Error! Bookmark not defined.  
 Screening, if applicable  ............................................................................................................... 20 
 Point of Enrollment  ...................................................................................................................... 20 
 Scheduled Procedures  ................................................................................................................ 21 
6.5.1  Baseline  ................................................................................................................................... 21 
6.5.2  Randomiz ation, if applicable ................................................................................................... 21 
6.5.3  Implant/Procedure  .................................................................... Error! Bookmark not defined.  
6.5.4  Scheduled Follow -ups .............................................................. Error! Bookmark not defined.  
 Patient Reported Outcome (PRO) Measures, if applicable ......................................................... 24 
6.6.1  PRO measure (Acronym or short name) (Reference)  .............. Error! Bookmark not defined.  
 Unscheduled Visits  ...................................................................................................................... 24 
 Study Flow Chart  ......................................................................................................................... 25 
 Health Care Economic Data Collection, if applicable  ................... Error! Bookmark not defined.  
 Description of Activities Performed by [INVESTIGATOR_391931], if applicable  .......................... [ADDRESS_534944] Withdrawal  ...................................................................................................................... 27 
 Requirements for Clinical Laboratories, if applicable  ................... Error! Bookmark not defined.  
6.13.1  Central Lab  ........................................................................... Error! Bookmark not defined.  
 Requirements for Clinical Equipment, if applicable  ...................... Error! Bookmark not defined.  
 Study Committees, if applicable  ................................................... Error! Bookmark not defined.  
6.15.1  Steering Committee (SC)  ..................................................... Error! Bookmark not defined.  
6.15.2  Publication Committee (PC)  ................................................. Error! Bookmark not defined . 
6.15.[ADDRESS_534945] Selection Committee (SSC), if applicable  ............... Error! Bookmark not defined.  
6.15.[ADDRESS_534946] (DSMB), if applicable  ........... Error! Bookmark not defined.  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 6 of 41 
 
6.15.5  Clinical Events Committee (CEC)  ........................................ Error! Bookmark not defined.  
7 Statistical Considerations  ..................................................................................................................... 28 
 Hypotheses  .................................................................................................................................. 28 
7.1.1  Primary [Safety/Effectiveness] Endpoint Hypothesis(es)  ........................................................ 28 
7.1.2  Secondary [Safety/Effectiveness] Endpoint Hypothesis(es)  .... Error! Bookmark not defined.  
 Justification of Clinical Investigation Design  ............................................................................... 28 
 Multiplicity  .................................................................................................................................... 28 
 Overall Sample Size  .................................................................................................................... 28 
 Timing of Analysis  ....................................................................................................................... 28 
 Success Criteria  .......................................................................................................................... 29 
 Interim Analysis  ........................................................................................................................... 29 
 Statistical Criteria for Termination  ............................................................................................... 29 
 Deviations from Statistical Plan  ................................................................................................... 29 
8 Risks and Benefits  ............................................................................................................................... 29 
 Risks Associated with the Device Under Investigation  ............................................................... 29 
8.1.1  Anticipated Adverse Device Effects  ........................................................................................ 29 
8.1.2  Risks Associated with Clinical Investigation Assessments  ..................................................... 30 
 Risk Control Measures  ................................................................................................................ 30 
 Possible interactions with concomitant treatments  ..................................................................... 30 
 Anticipated Benefits  ..................................................................................................................... 30 
 Risk-to-Benefit Rationale  ............................................................................................................. 30 
 History of Device Modifications or Recall, if applicable  ................ Error! Bookmark not defined.  
[ADDRESS_534947], if applicable  .................. Error! Bookmark not defined.  
9.2.3  Device Deficiency (DD), if applicable  ....................................... Error! Bookmark not defined.  
9.2.4  Complaints, if applicable .......................................................................................................... 31 
 Source records  ............................................................................................................................ 32 
 Records Retention  ....................................................................................................................... 32 
10 Clinical Data Handling  ..................................................................................................................... 32 
 Protection of Personally Identifiable Information ......................................................................... 33 
 Data Management Plan  ............................................................................................................... 33 
 Document and Data Control  ........................................................................................................ 33 
10.3.1  Traceability of Documents and Data  ................................................................................... 33 
10.3.2  Recording Data  .................................................................................................................... 33 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 7 of 41 
 
11 Monitoring  ........................................................................................................................................ 33 
12 Compliance Statement  .................................................................................................................... 33 
 Statement of Compliance  ............................................................................................................ 33 
 Quality Assurance Audits and Regulatory Inspections  ............................................................... 34 
 Repeated and Serious Non -Compliance  ..................................................................................... 34 
13 Suspension or Premature Termination of the Clinical Investigation  ............................................... 34 
14 Clinical Investigation Conclusion  ..................................................................................................... 35 
15 Publication Policy  ............................................................................................................................ 35 
16 Reporting Results on ClincalTrials.gov Website, if applicable  ......... Error! Bookmark not defined.  
Appendix A: CIP Revisions  ......................................................................................................................... 36 
Appendix B: Definitions  ............................................................................................................................... 37 
Appendix C: Labels  ...................................................................................... Error! Bookmark not defined.  
Appendix D: Bibliography  ............................................................................................................................ 39 
Appendix E: Case Report Form  .................................................................................................................. 40 
Appendix F: Informed Consent Form  .......................................................................................................... 41 
 
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534948] stimulation (SCS) patients with chronic intractable back and/or leg pain.  Microdosing 
BurstDRTM consists of periods during which stimulation is delivered with standard BurstDRTM stimulation 
parameters alternated with periods dur ing which no stimulation is being delivered. Previous results show 
that patients using  standard BurstDRTM can be programmed with microdosing with no changes to 
therapeutic efficacy  (Vesper et. al, 2017) . In this study we propose to evaluate therapeutic  efficacy of 
BurstDRTM microdosing , and determine optimal microdosing programming parameters  in chronic pain 
patients , who are eligible for SCS therapy . 
 Objective(s)  
• The primary objective is to evaluate the efficacy of BurstDRTM microdosing stimulation in patients 
with chronic intractable back and/or leg pain with no prior history of SCS therapy .  
• The secondary objectives are to evaluate the optimal microdosing program, evaluate the long 
term efficacy of BurstDRTM stimulation on patient’s pai n intensity, and evaluate the improvements 
in quality of life, disability , anxiety, depression, catastrophizing and overall satisfaction . 
 Devices Used 
The following devices will be used in this clinical investigation:  
 
Table 1: Identification of Devices un der Investigation  
Device name  [CONTACT_26159]/Type  Manufacturer  Region/ Country  Investigational or Market 
Released  
Abbott Invisible trial external pulse 
generator (EPG)  3599 (Base), 3032 
(Header)  Abbott  US/OUS  Released 
Abbott Invisible trial Clinician 
Programmer  3870, 3872 Abbott  US/OUS  Released 
Abbott Invisible trial Patient Controller  3871, 3873  Abbott  US/OUS  Released  
Abbot Percutaneous trial lead 31XX Abbott  US/OUS  Released 
Abbott Lead extension 33XX Abbott  US/OUS  Released 
Abbott Prodigy internal pulse generator 
(IPG)  3799 Abbott  US/OUS  Released 
Abbott Prodigy MRI IPG  3772  Abbott  US/OUS  Released  
Abbott Prodigy Charger  3730  Abbott  US/OUS  Released  
Abbott Prodigy Patient Programmer  3856  Abbott  US/OUS  Released  
Abbott Rapid Programmer 
programming device  3835 Abbott  US/OUS  Released 
Abbott Proclaim IPG  3660, 3662  Abbott  US/OUS  Released  
Abbott Clinician Programmer App  3874  Abbott  US/OUS  Released  
Abbott Patient Controller App  3875  Abbott  US/OUS  Released  
Abbott commercially available 
percutaneous leads  31X6, 318X, 314X, 
315X, 316X  Abbott  US/OUS  Released 
Abbott  commercially available paddle 
leads  322X, 321X, 328X, 
324X, 326X, 3240  Abbott  US/OUS  Released 
Abbott Cinch™ Lead Anchor  1194  Abbott  US/OUS  Released  
Abbott Swift -Lock™ Anchor  1192  Abbott  US/OUS  Released  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 9 of 41 
 
 Design 
This is a prospective, open label, multicenter feasibility trial to evaluate the therapeutic efficacy of different 
BurstDRTM microdosing patterns in patients with chronic intractable pain.  
 Subjects , eligible for SCS therapy, who are diagnosed with chronic intractable back and/or leg pain,  will 
be considered for inclusion in this study. After baseline evaluation, subjects will undergo a SCS trial using the Abbott Invisible Trial system.  During the trial implant phase, SCS leads will be i mplanted in the dorsal 
column based on physician discretion. According to standard clinical practices performed in the [LOCATION_002] (US), the trial phase will last around 3- 7 days. At the start of the trial phase, patients will be 
programmed with the firs t ON/OFF stimulation pattern (30 second STIM ON, 90 seconds STIM OFF).  
Patients who do not achieve adequate pain relief (at least 50% reduction in back and/or leg VAS from 
baseline) within the first 3- 4 days will be reprogrammed to a new ON/OFF stimulation pattern (5 seconds 
ON/ 15 seconds OFF) . Patients , who still do not achieve adequate pain relief within [ADDRESS_534949] 50% pain relief (according to average back and/or leg VAS) using one of the two microdosing burst stimulation paradigms will be considered f urther participation in 
the study.  See Figure 1.  
 
 
Fig 1: Representation of the decision making algorithm for the SCS trial phase of the study  
 

 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534950] received permanent implantation will be programmed 
based on the stimulation mode used for their trial success. Pain intensity, quality of life, disability, anxiety, 
depression, pain catastrophizing, satisfaction,  and medication usage will be assessed at baseline, after 
SCS trial and at the 1, 3 and 6 month follow up. Adverse events will be collected throughout the study period.  
 During the month leading to the 1 month follow up visit, patients’ pain r elief will be evaluated on a weekly 
basis  according to Figure 2 . Briefly, p atients who do not achieve adequate pain relief  (greater or equal to 
pain relief achieved during the trial phase)  will try lower stimulation ON/OFF ratios to determine the lowest 
possible stimulation ratio whilst maintaining adequate pain relief. This stimulation ON/OFF ratios will start from a ratio of 1:12 (Program 1) and increase to a potential ON/OFF ratio of 1:3 (Program 5)  – Once the 
most optimal microdosing program is determined (as per algorithm in Figure 2), the patient will continue the rest of the study with that program.   If inadequate pain relief is experienced anytime during the study, 
the BurstDR
TM microdosing parameters will be altered as per the algorithm in Figure 2.  
 
Option 1 : Patients who underwent a  successful 
trial using 30s ON: 90s OFF  BurstDRTM 
microdosing  Option 2: Patients who underwent a successful 
trial using 5s ON: 15s OFF  BurstDRTM 
microdosing  
  
Figure 2: Representation of the decision making algorithm for the SCS [ADDRESS_534951] permanent implant  
phase of the study  
 The total duration of the study is expected to be 2 years.  
 The clinical study will be conducted in up to 6 centers in the [LOCATION_002]  
 
Up to 60  subjects will be enrolled in this study.  

 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 11 of 41 
 
 Endpoints  
There is 1 primary endpoint  and 3 secondary endpoints in this clinical investigation.  
1.4.1  Primary Endpoints  
• Evaluate the change in pain intensity between baseline, trial and long- term follow up evaluations 
using the Visual Analog Scale (VAS) assessments.  
1.4.2  Secondary Endpoints  
• Evaluate the optimal microdosing program  required  to maintain optimal pain relief on a patient 
specific bas is 
• Evaluate the change in European Quality of life – 5 Dimensions (EQ -5D) scores between 
baseline, SCS trial and follow up visits  
• Evaluate the change in Oswestry Disability Index (ODI) scores between baseline, SCS trial and 
follow up visits  
• Evaluate the change in Hospi[INVESTIGATOR_423578] (HADS ) scores between baseline, 
SCS trial and follow up visits  
• Evaluate the change in Pain Catastrophizing Scale  (PCS)  scores between baseline, SCS trial 
and follow up visits  
• Evaluate the change in Patient Global Impression of Change (PGIC) between SCS trial and 
follow  up visits  
• Evaluate the change in medication usage between baseline, SCS trial and follow up visits  
1.4.3  Descriptive Endpoint(s) 
Descriptive endpoints are reported using only summary statistics and no hypothesis tests will be 
performed.  
 
• Optimal microdosing pro gram  
• Medication Usage  
 Study Population  
The intended population of this clinical investigation consists of patients diagnosed with chronic 
intractable back and/or leg pain with no prior history of neuromodulation therapi[INVESTIGATOR_014].  
 Inclusion/Exclusion Criteria  
1.6.1  Inclusion Criteria  
• Subject is able to provide informed consent to participate in the study;  
• Subject diagnosed with chronic intractable pain associated with back and/or limbs ; 
• Subject is 18 years of age or older;  
• Subject has failed to respond to at least 6 months of conventional treatment  which may include 
pharmacological treatment, physical therapy, epi[INVESTIGATOR_260794];  
• Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the average back 
and/or leg pain VAS at baseline;  
• Subject ’s medical record has been evaluated by [CONTACT_423598] a 
good candidate for a neurostimulation system;  
• Subject is on  stable pain medications with a total opi[INVESTIGATOR_423579] 28 days prior to enrolling in 
this study, and  i s willing to stay on those medications with no dose increase until the 3 month 
visit; 
• Subject is willing to cooperate with the study requirements including compliance with the regimen 
and completion of all office visits;  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 12 of 41 
 
• Female candidates of child- bearing potential agree to commit to the use of an effective method of 
contraception (including but not limited to sterilization, barrier devices, oral contraceptives, 
intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the stud y 
1.6.2  Exclusion Criteria  
• Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive 
peripheral vascular disease, post -herpetic neuralgia or uncontrolled diabetes mellitus;  
• Subject is currently participating in a clinical investi gation that includes an active treatment arm;  
• Subject has been implanted with or participated in a trial period for a neurostimulation system;  
• Subject has an infusion pump;  
• Subject has evidence of an active disruptive psychological or psychiatric disorder as determined 
as per standard of care;  
• Subject has a current diagnosis of a progressive neurological disease as determined by [CONTACT_3786];  
• Subject is immunocompromised;  
• Subject has an existing medical condition that is likely to require repetitive MRI  evaluation in the 
future (i.e. epi[INVESTIGATOR_002], stroke, multiple sclerosis, acoustic neuroma, tumor);  
• Subject has history of cancer requiring active treatment in the last 12 months;  
• Subject has an existing medical condition that is likely to require the use of diathermy in the future;  
• Subject has documented history of allergic response to titanium or silicone;  
• Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;  
• Subject is a female candidates of child bearing potential that are pregnant (confirmed by [CONTACT_423599]/blood pregnancy test);  
• Subject has life expectancy of less than 6 months ; 
• Subject is involved in an injury claim under current litigation  
 Enrollment  
A patient becomes a subject once he/she has been fully informed about the study, has agreed to 
participate, signed & dated the consent . 
 Study Assessments 
Subjects will undergo a baseline assessment to collect primary and secondary outcome measures prior to 
the SCS trial. Specifically, baseline assessments will include: pain rating as assessed by [CONTACT_198064], quality 
of life as assessed by [CONTACT_28973] -5D, disability as assessed by [CONTACT_212855] , anxiety and depression as assessed by [CONTACT_423600],  and pain catastrophizing as assessed by [CONTACT_423601]. Medication usage will also be collected during 
the baseline visit.  
 Subjects will be implanted with trial SCS system according to clinical practice and practitioner’s discretion. At the end of the SCS trial period, subjects who experienced a reduc tion of 50% or more in average pain 
back and/or leg VAS scores  with one of  the two microdosing stimulation paradigms  will be offered 
permanent implant and further participation in the study. The same primary and secondary outcomes measures will be collecte d at the end of the SCS trial period as well as at the 1 , 3 and 6 months follow up 
visit, with the inclusion of patient satisfaction as assessed by [CONTACT_162191]. Programming parameters  will 
also be assessed during these visits.  
2 Introduction 
This document is a clinical investigation  plan (CIP) for the BOLD clinical investigation. This clinical 
investigation is intended to evaluate the therapeutic efficacy of microdosing BurstDRTM stimulation in 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534952] stimulation (SCS) patients with chronic intractable back  and/or leg pain. This clinical 
investigation is sponsored by [CONTACT_69735] . 
 
This clinical investigation will be conducted in accordance with this CIP. All parties involved in the conduct of the clinical investigation will be qualified by [CONTACT_8640], training, or  experience to perform their tasks and 
this training will be documented appropriately.  
[ADDRESS_534953] stimulation (SCS) is increasingly being used as an alternative for the treatment of chronic, intracta ble pain. In a systematic meta- analysis of the literature, Taylor et al. (2006) reported that SCS 
reduces pain, improves quality of life, reduces analgesic use, allows some patients to return to work and may also result in significant cost savings over tim e, while having minimally significant adverse events in 
patients with neuropathic back and/or leg pain.  
 Patients receiving conventional tonic SCS (electrical pulses delivered in the 40- 60Hz stimulation 
frequency range) experience paresthesia or a tingling  sensation. Burst SCS is a newer paradigm that is 
currently approved worldwide.  Burst stimulation eliminates or greatly reduces the incidence of paresthesia 
(Courtney et al. 2014), and it entails delivering groups of pulses called burst trains (A) repeated  at a burst 
rate (B); within each burst train, several pulses are issued at an intra- burst rate (C) (See Figure 3 ). 
Individual pulses are characterized by a pulse amplitude (D) and pulse width.  
 Figure 3: 
 
  While the efficacy of standard burst stimulation parameters is known (Courtney et al. 2014, DeRidder et 
al., 2010, 2013), its comparison to more energy efficient settings is unknown.  
 
Burst microdosing consists of delivery of intermittent doses of burst s timulation. Preliminary evidence 
supports that  the therapeutic efficacy of burst microdosi ng result s in a similar clinical outcome compared 
to standard burst stimulation (Vesper et al. 2017) . Use of these new energy efficient stimulation 
parameters has the potential to prolong the battery life of a non- rechargeable, primary cell Implantable 

 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 14 of 41 
 
Pulse Generator (IPG). It also has the potential to improve patient convenience by [CONTACT_423602] a non- primary cell IPG . 
In this study, we aim to evaluate the therapeutic efficacy of different BurstDRTM microdosing patterns in 
patients with chronic intractable pain  
4 Device(s) Under Investigation  
 Identification and Description of the Devices under investigation  
4.1.1  Identificatio n 
 
Table 2: Identification of Devices under Investigation  
Device name  [CONTACT_26159]/Type  Manufacturer  Region/ Country  Investigational or 
Market Released  
Abbott Invisible trial external 
pulse generator (EPG)  3599 (Base), 
3032 (Header)  Abbott  US/OUS  Released  
Abbott Invisible trial Clinician 
Programmer  3870, 3872  Abbott  US/OUS  Released  
Abbott Invisible trial Patient 
Controller  3871, 3873  Abbott  US/OUS  Released  
Abbot Percutaneous trial lead  31XX  Abbott  US/OUS  Released  
Abbott Lead extension  33XX  Abbott  US/OUS  Released  
Abbott Prodigy internal pulse 
generator (IPG)  3799  Abbott  US/OUS  Released  
Abbott Prodigy MRI IPG  3772  Abbott  US/OUS  Released  
Abbott Prodigy Charger  3730  Abbott  US/OUS  Released  
Abbott Prodigy Patient 
Programmer  3856  Abbott  US/OUS  Released  
Abbott Rapid Programmer 
programming device  3835  Abbott  US/OUS  Released  
Abbott Proclaim IPG  3660, 3662  Abbott  US/OUS  Released  
Abbott Clinician Programmer 
App 3874  Abbott  US/OUS  Released  
Abbott Patient Controller App  3875  Abbott  US/OUS  Released  
Abbott commercially available 
percutaneous leads  31X6, 318X, 
314X, 315X, 
316X  Abbott  US/OUS  
Released  
Abbott  commercially available paddle leads  322X, 321X, 
328X, 324X, 
326X, 3240  Abbott  US/OUS  
Released  
Abbott Cinch™ Lead Anchor  1194  Abbott  US/OUS  Released  
Abbott Swift -Lock™ Anchor  1192  Abbott  US/OUS  Released  
 
4.1.2  Device Description and Intended P urpose  
Abbott Invisible trial external pulse generator (EPG):  a 16 channels, software controlled, battery 
powered, and external stimulator that generates the electrical pulses to be used during the trial phase of the study  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 15 of 41 
 
Abbott Invisible trial Clinician Programmer: software compatible with iOS™ App 8.1 or later to be 
used on iPad mini™; enables the clinician to program the Abbott  Invisible trial EPG  
Abbott Invisible trial Patient Controller: software compatible with iOS™ App 8.1 or later to be used on 
iPad touch™; en ables patient -controlled therapy adjustment of the Abbott  Invisible trial EPG  
Abbott Percutaneous trial lead: sterile  stimulating electrode placed in the epi[INVESTIGATOR_423580]: sterile extension that connects the pulse generator to the stimulating electrode  
Abbott Prodigy: a 16 channels, software controlled, rechargeable battery powered, internal stimulator to 
be used during the follow up phase of the study that generates the electrical pulses.  
Abbo tt Prodigy MRI: a 16 channels, software controlled, rechargeable battery powered, internal 
stimulator to be used during the follow up phase of the study that generates the electrical pulses.  
Abbott Prodigy Charger: The IPG Charging System provides the capability to recharge the IPG battery 
while stimulation is either on or off.  The charging system has several main parts: AC line cord, AC power 
supply, power cable, and charger antenna.  The charger transmits RF energy through the antenna to the 
IPG battery to recharge it.  
Abbott Patient Programmer: the patient programmer allows subjects to adjust stimulation intensity and 
to select a different stimulation programs in the Prodigy MRI IPG.  
Abbott Rapid Programmer: the rapid programmer enables the clinician to program the Prodigy IPG.   
Abbott Proclaim internal pulse generator (IPG): a 16 channels, software controlled, battery powered, 
internal stimulator to be used during the follow up phase of the study that generates the electrical pulses  
Abbott Clinician Pro grammer App: software compatible with iOS™ App 8.3 or later to be used on iPad 
mini™; enables the clinician to program the Proclaim IPG  
Abbott Patient Controller App: software compatible with iOS™ App 8.1 or later to be used on iPad touch™; enables patient -controlled therapy adjustment of the Proclaim IPG  
Abbott percutaneous leads  lead: sterile  stimulating electrode that are placed in the epi[INVESTIGATOR_423581]égé IPG 
Abbott paddle leads: sterile stimulati ng electrodes that are placed in the epi[INVESTIGATOR_423582]égé IPG  
Abbott Cinch™ Lead Anchor: securing device designed to reduce lead migration and breakage 
Abbott Swift -Lock™ Anchor: securing device designed t o red uce lead migration and breakage 
4.1.[ADDRESS_534954]
TM microdosing patterns in patients with chronic intractable pain.  
 Subjects diagnosed with chronic intractable back and/or leg pain, with no prior history of SCS therapy, will be considered for inclusion in this study. After baseline evaluation, subjects w ill undergo a SCS trial using 
the Abbott Invisible Trial system.  During the trial implant phase, SCS leads will be implanted in the dorsal column based on physician discretion. According to standard clinical practices performed in the [LOCATION_002] (US), the trial phase will last around 3- 7 days. At the start of the trial phase, patients will be 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534955] ON/OFF stimulation pattern (30 second STIM ON, 90 seconds STIM OFF).  
Patients who do not achieve adequate pain relief (at least 50% reduction in back and/or leg VAS from 
baseline) within the first 3- 4 days will be reprogrammed to a new ON/OFF stimulation pattern (5 seconds 
ON/ 15 seconds OFF) . Patients , who still do not achieve adequate pain relief within [ADDRESS_534956] 50% pain relief (according to average back and/or leg VAS) 
using one of the two microdosing burst stimulation paradigms will be considered further participation in the study.  See Figure 1.  
 Patients who have passed the trial phase and have received permanent implantation will be  programmed 
based on the stimulation mode used for their trial success. Pain intensity, quality of life, disability,  anxiety, 
depression,  pain catastrophizing, satisfaction,  and medication usage will be assessed at baseline, after 
SCS trial and at the 1, 3 and 6 month follow up. Adverse events will be collected throughout the study 
period.  
 During the month leading to the 1 month follow up visit, patients’ pain relief will be evaluated on a weekly basis  according to Figure 2 . Briefly, p atients who do not achieve adequate pain relief  (greater or equal to 
pain relief achieved during the trial phase)  will try lower stimulation ON/OFF ratios to determine the lowest 
possible stimulation ratio whilst maintaining adequate pain relief. This stimulation ON/OFF rati os will start 
from a ratio of 1:12 (Program 1) and increase to a potential ON/OFF ratio of 1:3 (Program 5) –  Once the 
most optimal microdosing program is determined (as per algorithm in Figure 2), the patient will continue 
the rest of the study with that program.  If inadequate pain relief is experienced anytime during the study, the BurstDRTM microdosing parameters will be altered as per the algorithm in Figure 2.  
 
Option 1:  Patients who underwent a  successful 
trial using 30s ON: 90s OFF  BurstDRTM 
microdosi ng Option 2: Patients who underwent a successful 
trial using 5s ON: 15s OFF  BurstDRTM 
microdosing  
  

 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 17 of 41 
 
Figure 2: Representation of the decision making algorithm for the SCS [ADDRESS_534957] stimulation (SCS) patients with chronic intractable back and/or leg pain.  
5.2.1  Primary Objectives  
• To evaluate efficacy of microdosing BurstDRTM stimulation in patients with chronic intractable 
back and/or leg pain that have never received neuromodulation treatments before.  
 
5.2.2  Secondary Objectives  
• Evaluate the optimal microdosing program required  to maintain optimal pain relief on a patient 
specifi c basis  
• Evaluate the long term efficacy of BurstDRTM stimulation on patients’ pain intensity  
• Evaluate the improvements in quality of life, disability,  anxiety, depression,  catastrophizing , 
medication and overall satisfaction of patients using microdosing BurstDRTM stimulation  
 Endpoints  
There is 1 primary endpoints and 7  secondary endpoints in this clinical investigation.  
5.3.1  Primary Endpoint  
• Evaluate the change in pain intensity between baseline, trial and long- term follow up evaluations 
using the Visual Analog Scale (VAS) assessments.  
5.3.2  Secondary Endpoint 
• Evaluate the optimal microdosing program required  to maintain optimal pain relief on a patient 
specific basis  
• Evaluate the change in European Quality of life – 5 Dimensions (EQ -5D) scores between 
baseline, SCS trial and follow up visits  
• Evaluate the change in Oswestry Disability Index (ODI) scores between baseline, SCS trial and 
follow up visits  
• Evaluate the change in Hospi[INVESTIGATOR_5620] (HADS) scores between baseline, 
SCS trial and follow up visits  
• Evaluate the change in Pain Catastrophizing Scale  (PCS) scores between baseline, SCS trial and follow up visits  
• Evaluate the change in Patient Global Impression of Change (PGIC) between SCS trial and 
follow up visits  
• Evaluate the change in medication usage between baseline, SCS trial and follow up visits  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 18 of 41 
 
5.3.3  Descriptive Endpoint(s) 
Descriptive endpoints are reported using only summary statistics and no hypothesis tests will be 
performed.  
 
• Optimal microdosing program  
• Medication Usage  
 Study Population  
The intended population of this clinical investigation consists of patients diagnosed with chronic intractable back and/or leg pain with no prior history of neuromodulation therapi[INVESTIGATOR_014].  
5.4.1  Inclusion Criteria  
• Subject is able to provide informed consent to participate in the study;  
• Subject diagnosed with chronic intractable pain associated with back and/or limbs ; 
• Subject is 18 years of age or older;  
• Subject has failed to respond to at least 6 months of conventional treatment  which may include 
pharmacological treatment, physical therapy, epi[INVESTIGATOR_260794];  
• Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the average back 
and/or leg pain VAS at baseline;  
• Subject’s medical  record has been evaluated by [CONTACT_423598] a 
good candidate for a neurostimulation system;  
• Subject is on  stable pain medications with a total opi[INVESTIGATOR_423579] 28 days prior to enrolling in 
this study, and  is willing to stay on those medications with no dose increase until the 3 month 
visit; 
• Subject is willing to cooperate with the study requirements including compliance with the regimen 
and completion of all office visits;  
• Female candidates of child- bearing potential agree to commit to the use of an effective method of 
contraception (including but not limited to sterilization, barrier devices, oral contraceptives, 
intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study  
5.4.2  Exclusio n Criteria  
•  Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive 
peripheral vascular disease, post -herpetic neuralgia or uncontrolled diabetes mellitus;  
• Subject is currently participating in a clinical investigation th at includes an active treatment arm;  
• Subject has been implanted with or participated in a trial period for a neurostimulation system;  
• Subject has an infusion pump;  
• Subject has evidence of an active disruptive psychological or psychiatric disorder as determ ined 
as per standard of care;  
• Subject has a current diagnosis of a progressive neurological disease as determined by [CONTACT_3786];  
• Subject is immunocompromised;  
• Subject has an existing medical condition that is likely to require repetitive MRI evaluati on in the 
future (i.e. epi[INVESTIGATOR_002], stroke, multiple sclerosis, acoustic neuroma, tumor);  
• Subject has history of cancer requiring active treatment in the last 12 months;  
• Subject has an existing medical condition that is likely to require the use of diathermy in the 
future;  
• Subject has documented history of allergic response to titanium or silicone;  
• Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;  
• Subject is  a female candidates of child bearing potential that are pregnant (confirmed by [CONTACT_423599]/blood pregnancy test);  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 19 of 41 
 
• Subject has life expectancy of less than 6 months ; 
• Subject is involved in an injury claim under current litigation  
[ADDRESS_534958] be received prior to initiating 
study procedures.  
 Patients will be informed about the study to determine if he/she is interested in participating.  Eligible 
patients will read, sign and date the informed consent and will continue to participate in the study as subjects . Subjects diagnosed with chronic intractable back and/or leg pain, with no prior history of SCS 
therapy, will be considered for inclusion in this study  and will be assessed at baseline and all follow up 
visits.  
 The ass essments will include:  
• Pain intensity as assessed b y the Visual Analog Scale (VAS)  
• Quality of life as assessed by [CONTACT_423603] –  5 Dimensions (EQ -5D) 
• Disability as assessed by [CONTACT_212853] (ODI)  
• Anxiety and Depression as assessed by [CONTACT_80826][INVESTIGATOR_5620] (HADS)  
• Pain Catastrophizing as assessed by [CONTACT_208791] (PCS)  
• Satisfaction as assessed by [CONTACT_72495] (PGIC)  
• Medication Usage  
• Adverse Events  
 After baseline evaluation, subjects will undergo a SCS trial using the Abbott Invisible Trial system. During 
the trial implant phase, SCS leads will be implanted in the dorsal column based on physician discretion. According to standard clinical practices performed in th e [LOCATION_002] (US), the trial phase will last 
around 3- [ADDRESS_534959] ON/OFF 
stimulation pattern (30 second STIM ON, 90 seconds STIM OFF).  Patients who do not achieve adequate pain rel ief (at least 50% reduction in back and/or leg VAS from baseline) within the first 3- 4 days will be 
reprogrammed to a new ON/OFF stimulation pattern (5 seconds ON/ 15 seconds OFF) . Patients , who still 
do not achieve adequate pain relief within [ADDRESS_534960] 50% pain relief (according to average back and/or leg VAS) using one of the two microdosing burst stimulation paradigms will be considered further participation in the study.  See Figure 1.  
 Patients who have passed the trial phase and have received permanent implantation will be programmed based on the stimulation mode used for their trial success. Pain intensity, quality of life, disability, anxiety, 
depression, pain catastrophizing, satisfaction, and medication usage will be assessed at baseline, after 
SCS trial and at the 1, 3 and 6 month follow up. Adverse events will be collected throughout the study 
period.  
 
During the month leading to the 1 month follow up visit, patients’ pain relief will be evaluated on a weekly 
basis  according to Figure 2 . Briefly, p atients who do not achieve adequate pain relief  (greater or equal to 
pain relief achieved during the trial phase)  will try lower stimulation ON/OFF ratios to determine the lowest 
possible stimulation ratio whilst maintaining adequate pain relief . This stimulation ON/OFF ratios will start 
from a ratio of 1:12 (Program 1) and increase to a potential ON/OFF ratio of 1:3 (Program 5) –  Once the 
most optimal microdosing program is determined (as per algorithm in Figure 2), the patient will continue 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534961] of the study with that program.  If inadequate pain relief is experienced anytime during the study, 
the BurstDRTM microdosing parameters will be altered as per the algorithm in Figure 2.  
 
The following sections provide a detailed description of procedures required by [CONTACT_20812]. 
 Informed Consent Process 
The P rincipal Investigator or his/her authorized designee will conduct the Informed Consent Process, as 
required by [CONTACT_26137]’s IRB/EC. This process will include a verbal disc ussion 
with the subject on all aspects of the clinical investigation that are relevant to the subject’s decision to participate, such as details of clinical investigation procedures, anticipated benefits, and potential risks of clinical investigation parti cipation.  During the discussion, the Principal Investigator [INVESTIGATOR_022]/her authorized 
designee will avoid any improper influence on the subject and will respect subject’s legal rights. The subject shall be provided with the informed consent form written in a l anguage that is understandable to 
the subject and has been approved by [CONTACT_16018]’s IRB/EC. The subject shall have adequate time to 
review , ask questions  and consider participation.  
 If the subject agrees  to participate, the Informed Consent form must be s igned and dated by [CONTACT_423604]. The signed original will be filed in the subject’s hospi[INVESTIGATOR_423583], and a copy  will be provided to the subject.  
 The Principal I nvestigator or his/her authorized designee w ill document the informed consent process in 
the subject’s hospi[INVESTIGATOR_3491]/or research charts. The date of signatur e will be entered on an applicable Case 
Report Form ( CRF).  
 Failure to obtain informed consent from a subject prior to clinical investigation  enrollment should be 
reported to Sponsor  within 5 working days and to the reviewing center’s IRB/EC according to the IRB’s/ 
EC’s reporting requirements.  
 
If, during the clinical investigation, new information becomes available that can significantly affec t a 
subject's future health and medical care, the Principal Investigator [INVESTIGATOR_022]/her authorized designee will 
provide this information to the subject. If relevant, the subject will be asked to confirm their continuing 
informed consent in writing.  
 Screening  
Potential patients presenting at the investigational sites will be fully informed about the clinical investigation, following the established Informed Consent process  (described in section 6.1) . Once a duly 
dated and signed Informed Consent Form is obtained, the screening procedures may begin.  
 Records of patients who are screened must  be maintained.  
 In case the subject does not meet all inclusion criteria or meets any of the exclusion criteria, the subject is considered a screening failure.  The Principal  Investigator [INVESTIGATOR_423584] a  screening l og as required.  
 Point of Enrollment  
Subject is  considered enrolled in the clinical investigation from the moment the subject has provided a 
written  Informed Consent and has  been confirmed to meet all inclusion criteria and none of the exclusion 
criteria.  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534962] enrollment information (name [CONTACT_294270], date of consent and Inclusion/exclusion information) in the hospi[INVESTIGATOR_423585] a timely manner.  
 Notification of enrollment to the Sponsor is considered to have occurred when the Sponsor has received 
the applicable CRF .
 
 Scheduled Procedures  
The Principal I nvestigator is responsible for ensuring all clinical investigation data is collected as required 
per CIP scheduled procedures.  
6.4.1  Baseline  
Baseline visit activities can occur at the same visit of enrollment after the informed consent has been obtained.   
 The following assessments and information will be collected at the baseline visit  
• Demographics - include subject’s Age and Gender  
• Physical examination-  include subject’s height and weight  
• Indication for device/ procedure  
• Previous therapi[INVESTIGATOR_423586]  
• Clinical investigation specific examinations  
 Pain intensity  as assessed by [CONTACT_198064]  
 Quality of life as assessed by [CONTACT_20367]5D  
 Disability as assessed by [CONTACT_423605]  
 Anxiety and Depression as assessed by [CONTACT_183535]  
 Pain Catastrophizing as assessed by [CONTACT_423601]  
 Medication Usage  
  
Timing of visit  Activities at visit  Case Report Form  
Scree ning/Baseline • Subject assesses pre-trial pain levels, quality of 
life, disability,  anxiety, depression,  pain 
catastrophizing , and medication usage.  
 • VAS Form  
• EQ-5D Form  
• ODI Form  
• HADS Form  
• PCS Form  
• Medication Usage Form  
 
6.4.[ADDRESS_534963] clinical practices performed in the [LOCATION_002] (US), the trial phase will last around 3- [ADDRESS_534964] ON/OFF 
stimulation pattern (30 second STIM ON, 90 seconds STIM OFF).  Patients who do not achieve adequate pain relief (at least 50% reduction in back and/or leg VAS from baseline) within the first 3- 4 days will be 
reprogrammed to a new ON/OFF stimulation pattern (5 seconds ON / 15 seconds OFF). Patients, who still 
do not achieve adequate pain relief within [ADDRESS_534965] 50% 
pain relief (according to average back and/or leg VAS) using one of the two microdosing burst stimulation paradigms will be considered further participation in  the study . Patients who still do not achieve adequate 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 22 of 41 
 
pain relief will be reprogrammed to a continuous mode of BurstDRTM stimulation and their trial evaluation 
will continue. These patients will be evaluated for an additional 2 days . 
 
The following assess ments and information will be collected at the SCS Trial visit  
• Surgery Form  
• Clinical investigation specific examinations  
 Programming Form  
 The following activities will be performed at the SCS Trial visit:  
• SCS Trial Lead(s) Implant  
• EPG Device programming 
 
Timing of visit  Activities at visit  Case Report Form  
SCS Trial  • SCS trial lead implant  
• EPG programming  
 • Surgery Form  
• Programming Form  
 
 
6.4.3  End of Trial  
During the End of Trial visit, subjects will complete the same questionnaires completed during the baseline visit.  If the VAS score is < 50% of the VAS collected during the screening visit  and is not using 
the two microdosing burst stimulation paradigms, the subject will exit the study. Subjects whose VAS score at the end of the trial is >50% of the VA S collected during the screening visit  and is using one of the 
two microdosing burst stimulation paradigms,  will be considered for permanent lead and IPG 
implantation.  
 The following assessments and information will be collected at the End of Trial  visit: 
• Clinical investigation specific examinations  
 Pain level as assessed by [CONTACT_198064]  
 Quality of life as assess ed by [CONTACT_20367] -5D 
 Disability as assessed by [CONTACT_423605]    
 Anxiety and Depression as assessed by [CONTACT_183535]  
 Pain Catastrophizing as assessed by [CONTACT_423601]  
 Satisfaction as assessed by [CONTACT_162191]   
 Medication usage;  
 Programming Form  
 
Timing of visit  Activities at visit  Case Report Form  
End of Trial  • Subject assess pain levels, quality of life, disability,  
anxiety, depression,  pain catastrophizing, 
satisfaction, medication usage,  and programming   
 
 • VAS Form  
• EQ-5D Form  
• ODI Form  
• HADS Form  
• PCS Form  
• PGIC Form  
• Medication Usage Form  
• Programming Form  
 
 
6.4.[ADDRESS_534966] clinical practice . 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 23 of 41 
 
 
The following assessments and information will be collected at the Permanent Implant  visit 
• Surgery Form  
 The following activities will be performed at the Permanent Implant visit: 
• SCS Permanent Lead(s) Implant  
• IPG Implant  
 
Timing of visit  Activities at vi sit Case Report Form  
SCS Permanent  
Implant  • SCS permanent lead implant  
• IPG implant  • Surgery Form  
 
6.4.[ADDRESS_534967] programming techniques.  
 
The following assessments and information will be collected at the Activation visit 
• Clinical investigation specific examinations  
 Programming Form  
 
Timing of visit  Activities at visit  Case Report Form  
Activation  • IPG programming  
 • Programming Form  
 
6.4.[ADDRESS_534968]-activation visit with follow -up assessments at 1, 3 and 6 
months.  During each visit, subjects will complete the same questionnaires completed during the end of 
trial visit. 
The following assessments and information will be collected at the End of Trial  visit: 
• Clinical investigation specific examinations  
 Pain level as assessed by [CONTACT_198064]  
 Quality of life as assess ed by [CONTACT_20367] -5D 
 Disability as assessed by [CONTACT_423605]    
 Anxiety and Depression as assessed by [CONTACT_183535]  
 Pain Catastrophizing as assessed by [CONTACT_423601]  
 Satisfaction as assessed by [CONTACT_162191]  
 Medication usage;  
 Programming Form  
 
Timing of visit  Activities at visit  Case Report Form  
End of Trial  • Subject assess pain levels, quality of life , disability,  
anxiety, depression,  pain catastrophizing, 
satisfaction, medication usage,  and programming   
 
 • VAS Form  
• EQ-5D Form  
• ODI Form  
• HADS Form  
• PCS Form  
• PGIC Form  
• Medication Usage Form  
• Programming Form  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 24 of 41 
 
 
 Patient Reported Outcome (PRO)  Measures  
The Study Coordinator or designee will administer patient -reported outcome questionnaires. It is 
important the subject understands the meaning of all words and instructions in the questionnaires. The 
subject should be instructed to ask any questions about the questionnaires if further explanation is needed. Once the questionnaires are completed, the Study Coordinator or designee will review for completeness to verify that all questions have been answered according to the directions provided.  
 The following PRO measures will be collected according to the study requirements.  
 
• Pain level as assessed by [CONTACT_198064]  
• Quality of life as assessed by [CONTACT_20367] -5D 
• Disability as assessed by [CONTACT_941] O DI  
• Pain Catastrophizing as assessed by [CONTACT_423601]  
• Anxiety and Depression as assessed by [CONTACT_423606] a specified study visit.  Unscheduled visits may include subjects returning to t he office for an adverse event. The visit should be documented by [CONTACT_423607] (Adverse Event, Deviation, Death and/or 
Withdrawal Form.  
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534969] flow and requirements of this clinical 
investigation.  
 
Figure 1: Study Flow Chart  
 
 
 
  
 
  
 
  
 

 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 26 of 41 
 
 
 
Table 2: List of all clinical investigation specific tests and procedures  
 
                Visit  
 
 
Study Activity  Enrollment  
 Baseline  
 SCS Trial  
 End of 
Trial 
 SCS 
Implant  
 Activation  
 Follow -up 
Visits*  
 
Informed Consent 
Process  X       
Inclusion/Exclusion 
Criteria Screening  X       
VAS Assessment   X  X   X 
Enrollm ent Form  X       
EQ-5D Assessment   X  X   X 
ODI Assessment   X  X   X 
HADS Assessment   X  X   X 
PCS Assessment   X  X   X 
PGIC Assessment     X   X 
Trial System 
Implant    X     
Permanent System  
Implant      X X  
Adverse Event  (X) (X) (X) (X) (X) (X) (X) 
Deviation  (X) (X) (X) (X) (X) (X) (X) 
Termination  (X) (X) (X) (X) (X) (X) (X) 
Death  (X) (X) (X) (X) (X) (X) (X) 
(X) If applicable  
* Follow up visit assessments will be performed at months 1(30 ± 21 days), 3(90 ± 21 days) and (180 ± 
21 days)  
 Description of Activities P erformed by [CONTACT_423608].  
 Sponsor personnel may:  
• Provide technical support to the Investigators during trial  
 
Sponsor personnel will not:  
• Perform the informed consent process  
• Provide medical diagnosis or treatment to subjects  
• Discuss a subject’s condition or treatment with a subject without the approval and presence of a health care practitioner  
• Independently collect clinical investigational data  
 While S ponsor representatives may  perform these activities, the Principal I nvestigator remains 
responsible for ensuring all clinical investigation data is  collected as required per CIP.  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534970]’s future care will not be influenced by a decision, voluntary or otherwise, to withdraw from the 
study. All reasonable efforts should be made to retain the subject in the clinical study until completion of 
the study.  
 
Reasons for subject’s withdrawal include, but are not limited to:  
 
• Subject refuses to continue participating in the study  
• Subject does not meet the inclusion/exclusion criteria and does not require additional follow -up 
for safety reasons.  
• Subject is deceased (cause must be documented)  
• Subject’s non- compliance  
• Subject’s participation is terminated by [CONTACT_978] [INVESTIGATOR_115655], although the subject consented, 
since participation is no longer medically appropriate  
• Subject is ‘lost to follow up’: Subject does not adhere to the scheduled follow up visits but has not explicitly requested to be withdrawn from the clinical study. (This does not apply to mi ssed 
visits). Site personnel should at all times make all reasonable efforts to locate and communicate with the subject in order to achieve subject compliance to the scheduled follow up visits:  
 A subject will be considered ‘Lost to Follow Up’ after a minim um of [ADDRESS_534971]’s hospi[INVESTIGATOR_1097].  
 If these attempts are unsuccessful, a letter should be sent to the subject’s last 
known address or general practitioner (GP) and a copy of this letter should be maintained in the subject’s hospi[INVESTIGATOR_1097].  
 Note: If a subject misses one or more of the scheduled follow up visits (inclusive of the assigned visit windows), this will be considered as a missed visit. The subject may therefore still return for subsequent 
visits and will not be excluded from the study.  
 If a subject withdraws from the clinical study, the site will record the subject’s reasons for withdrawal, on a Withdraw al CRF.  
 When subject withdrawal from the clinical study is due to an adverse event the subject will be followed until resolution of that adverse event or determination that the subject’s condition is stable. The status of the subject’s condition should be documented at the time of withdrawal.   
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534972] will complete the questionnaires as in the 
previous follow up visit  and will exit the study . 
7 Statistical Considerations 
The following section describes the statistical methods for the clinical investigation and justification of the design. Additional details on statistical analyses, including sensitivity analyses, poolability analyses, subgroup analyses and analysis of desc riptive endpoint (s) may be maintained in a separate Statistical 
Analysis Plan (SAP).  
 Hypotheses  
This study is an open label , multi- center, feasibility study. Thus, there is no requirement for a formal 
hypothesis testing. We do anticipate improvements in primary and secondary outcomes. The results obtained in this study will potentially be used to generate a level -1 evidence based study with formal 
statistical hypotheses testing.  
7.1.1  Primary [Safety/Effectiveness] Endpoint Hypothesis(es)  
[IP_ADDRESS]  Analysis Methodology  
The primary analysis to assess improvement in pain intensity, using VAS, will be conducted using repeated measures ANOVA  (RMANOVA) . Post -hoc Tukey’s pairwise comparisons will follow to 
determine specific differences between follow -up visits. Secondary anal yses to assess improvements in 
quality of life, disability,  anxiety, depression catastrophizing and satisfaction will be conducted using 
repeated measures ANOVA  (RMANOVA)  or the most appropriate statistical methods.  
[IP_ADDRESS]  Sample Size Determination  
We will enroll approximately 60 subjects in  up to 4 study centers in the US. This study is a feasibility trial 
and no sample size calculations are required.  
 
[IP_ADDRESS]  Missing Data  
Missing data will be reported at each visit for each outcome. No imputations will be performed for  missing 
data.  
 Justification of Clinical Investigation Design  
This is a prospective, open label, multicenter feasibility trial to evaluate the therapeutic efficacy of different BurstDR
TM microdosing patterns in patients with chronic intractable pain.  Use of these new energy 
efficient stimulation parameters has the potential to prolong the battery life of a non- rechargeable, primary 
cell Implantable Pulse Generator (IPG). It also has the potential to improve patient convenience by [CONTACT_423609] a non- primary cell IPG.  Thus, it is crucial 
to evaluate these potential energy efficient stimulation parameters in SCS eligible patients.  
 Multiplicity  
All statistical tests will be performed with a type- 1 error rate 0.05, unless otherwise stated. Family -wise 
error for RMANOVA will be addressed using Tukey’s pairwise post -hoc comparisons.  
 Overall Sample Size  
We will enroll up to 6 0 subjects .  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534973] of care.  There are no additional risk s introduced to study 
subjects.  
 Risks Associated with the Device Under  Investigation  
We do not foresee any additional risk, beyond those normally associated with SCS therapy, described below.  
8.1.1  Anticipated Adverse Device Effects  
In addition to those risks commonly associated with surgery, the following risks are associated with implanting or using this neurostimulation system for SCS:  
 
• Undesirable changes in stimulation, which may be related to cellular changes in tissue around the electrodes, changes in electrode position, loose electrical connections, or lead failure  
• Lead migration, causing changes in stimulation and/or reduced pain relief  
• Epi[INVESTIGATOR_307865], hematoma, infection, spi[INVESTIGATOR_13377], or paralysis from 
placement of a lead in the epi[INVESTIGATOR_13814]  
• Cerebrospi[INVESTIGATOR_872] (CSF) leakage 
• Paralysis, weakness, clumsiness, numbness, or pain below the level of the implant  
• Persistent pain at the electrode or IPG site  
• Seroma (mass or swelling) at the IPG site  
• Infection of the lead extension at the exit zone during trial or infection of the IPG site 
• Allergic or rejection response to implant materials  
• Implant migration or skin erosion around the implant  
• Anticipated adverse device effects  
• Battery failure  
 
These adverse events and adverse device effects are not specific to the study, but related to the 
approved SCS implant procedure.  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534974] of 
care.  
 Risk Control Measures  
Every possible effort will be taken to minimize the risks, including:  
• Careful selection of experienced Investigators for the clinical investigation  
• Adequate monitoring for each clinical investigation site  
• Conducting the clinical investigation in accordance with the CIP, all applicable laws and 
regulations and any  conditions of approval imposed by [CONTACT_19821]/EC or applicable 
regulatory authorities where the clinical investigation is performed 
• Preparation of the SCS device and performance SCS implant procedure in accordance with the 
device IFUs  
• Training of Investigators on the CIP  
 Possible interactions with concomitant treatments  
There are no possible interactions with concomitant medical treatment and/or concurrent medical intervention beyond those associated with standard medical care using SCS.  
 Anticipat ed Benefits  
There are no additional clinical benefits associated with the participation in this study beyond those anticipated with standard clinical SCS  
 Risk -to-Benefit R ationale  
There are no additional  risk-to-benefits associated with the participation i n this study beyond those 
anticipated with standard clinical SCS . 
9 Requirements for Investigator Records and R eports  
 Deviations from CIP  
A deviation is defined as an instance(s) of failure to follow, intentionally or unintentionally, the requirements of the CIP. The investigator should not deviate from the CIP.  
 In some cases, failure to comply with the CIP may be considered failure to protect the rights, safety and well-being of subjects; such non- compliance exposes subjects to unreasonable risks. Examples:  failure to 
adhere to the inclusion/exclusion criteria, failure to perform safety assessments intended to detect adverse events. Investigators should seek to minimize such risks by [CONTACT_110596].  
 The PI [INVESTIGATOR_110567], complete, and current records, including documents showing the date of and reason for each deviation from the CIP. Relevant information for each deviation will be documented as soon as possible on the applicable CRF. The site will submit the CRF to the Sponsor.  
 The PI [INVESTIGATOR_423587]/EC.  
 Under emergency circumstances, deviations from the CIP to protect the rights, safety and well -being of 
subjects may proceed without prior approval of the Sponsor and the IRB/EC. Such deviations shall be documented and reported to the Sponsor and the IRB/EC as soon as possible.  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 31 of 41 
 
 Safety Reporting  
Safety surveillance within this study and the safety reporting performed both by [CONTACT_423610]. This is defined as from the time the [dilator/device 
delivery system has been introduced into the body . 
 The safety surveillance and the safety reporting will continue until the last investigational visit has been performed, the subject is deceased, the subject/investigator concludes his participation into the clinical investigation or the subject withdrawal from the clinical investigation.  
 
All adverse event data including deaths and device deficiency data (if applicable) will be collect ed 
throughout the clinical investigation and will be reported to the Sponsor on a CRF.  
 
Adverse events will be monitored until they are adequately resolved or the subject has ended his/her participation in the trial, whichever comes first. The status of the subject’s condition should be documented at each visit.  
 The investigator will report the event to the IRB/EC per their reporting requirements.  
 
Reportable events to sponsor are considered:  
 
• All Adverse Device Effects  
• All Serious Adverse Events (whether or not the event is considered device or procedure related and regardless the randomization group)  
• (if applicable) device deficiencies, that could have led to a serious adverse device effect  
 if either suitable action had not been taken;  
 if interv ention had not been made or  
 if circumstances had been less fortunate  
 
All events mentioned above will be reported to the Sponsor, as soon as possible, but no later than [ADDRESS_534975] notify the IRB/EC, if appropriate, in accordance with national and local laws and regulations, of the AEs reported to the Sponsor. All adverse events will be reported as per applicable regulatory requirements.  
9.2.[ADDRESS_534976] deaths are to be documented and reported to the sponsor within 72 hours after becoming aware of the event.  
All subjects’ deaths should be documented using the “Death Form” and a “Withdrawal Form” . 
9.2.[ADDRESS_534977] complete an AE CRF , including the information on 
the complaint and submit  to Abbott  as soon as possible.  
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534978] death be caused by [CONTACT_423611], the 
investigator should complete a Form 3500A (MedWatch) and submit to Abbott  and the FDA within 10 
days aft er becoming aware of the event.  
 Source r ecords  
Source documents will be created and maintained by [CONTACT_294258]. The data reported on the CRFs will be derived from, and be consistent with, these source documents, and any discrepancies will be explained in writing.  
 The following data can be recorded directly in the CRFs:  
• Pain VAS scores  
• EQ-5D scores  
• ODI scores  
• HADS scores  
• PCS scores  
• PGIC scores  
• Medication usage form  
• Programming form  
• Adverse events form  
 Records Retention  
The Sponsor and the Principal Investigators will maintain the clinical investigation documents as required. Measures  will be taken to prevent accidental or premature destruction of these documents. The Principal 
Investigator [INVESTIGATOR_354389]/party and document the 
transfer at the investigational site or the Sponsor’s facility , as appropriate . 
 These documents must be retained by [CONTACT_110602] a period of 2 years after  the conclusion 
of the clinical investigation and made available for monitoring or auditing by [CONTACT_1034]’s representative 
or representatives of the applicable regulatory agencies.  
 All original source documents must be stored for the maximum time required by [CONTACT_110603][INVESTIGATOR_307], research institute, or practice in question. If original source documents can no longer be maintained at the site, the investigator will notify the S ponsor.  
10 Clinical Data Handling 
The Sponsor will be responsible for the data handling.  The Sponsor and/or its affiliates will be responsible 
for compi[INVESTIGATOR_294215].  Data will be analyzed by [CONTACT_423612]’s locations worldwide  and/or any other worldwide 
regulat ory authority in support of a market -approval application.  
 During this study the following documents will be produced:  
• Patient’s ICF  
• Enrollment c ase report form 
• Inclusion/Exclusion c ase report form  
• VAS c ase report form  
• EQ-5D case report form  
• ODI case report form  
• HADS case report form  
• PCS c ase report form  
• PGIC c ase report form  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 33 of 41 
 
• Medication usage form  
• Programming form  
• Adverse events form  
 Protection of Personally Identifiable Information 
Abbott  respects and protects personally identifiable information collected or maintained for this clinical 
investigation. The privacy of each subject and confidentiality of his/her information will be preserved in 
reports and when publishing any data. Confidenti ality of data will be observed by [CONTACT_294260]. All data will be secured against unauthorized access.  
 Data Management Plan  
A Data Management Plan (DMP)  will describe procedures used for data review, database cleaning, and 
issuing and resolving data queries. If appropriate, the DMP may be updated throughout the clinical investigation duration. All revisions will be tracked and document controlled.  
 
Subject  data will be captured in a validated electronic data capture (EDC)  system hosted by [CONTACT_1034] . 
CRF received data for the clinical investigation will be entered by [CONTACT_423613]. An electronic 
audit trail will be used to track any subseque nt changes of the entered data.  
 Document and Data Control  
10.3.1  Traceability of Documents and Data  
The investigator will ensure accuracy, completeness legibility and timeliness of the data reported to the 
Sponsor on the CRFs and in all required reports.  
10.3.2  Recording Data  
The CRFs w ill be signed and dated by [CONTACT_110608]. Any change or correction to data 
reported on a paper CRF will be dated, initialed and explained if necessary, and will not obscure the 
original entry.  
11 Monitoring  
It is the responsibility of the S ponsor to ensure the clinical investigation is conducted, recorded and 
reported according to the approved CIP, subsequent amend ment(s), applicable regulations  and guidance 
documents.  
 
Centralized monitoring will occur through routine internal data review. This monitoring is designed to 
identify missing and inconsistent data, data outliers, and potential CIP  deviations that may be indicative of 
site non- compliance. On- site monitoring may occur at the discretion of the S ponsor.  
[ADDRESS_534979] current version of the World Medical Association (WMA) Declaration of Helsinki.  
 The investigator will sign a Clinical Trial Agreement and agrees to be compliant with it. The investigator will not start enrolling subjects or requesting informed consent from any subject prior to obtaining IRB/EC approval and relevant Regulatory  Authority approval, if applicable, and authorization from the S ponsor in 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 34 of 41 
 
writing for the clinical investigation . If additional requirements are imposed by [CONTACT_1201]/EC or relevant 
Regulatory  Authority, those requirements will be followed. If any action is taken by [CONTACT_2717]/EC or a 
relevant Regulatory  Authority  with respect to the clinical investigation, that information will be forwarded to 
the Sponsor . 
 
As the S ponsor, Abbott  has taken up general liability insurance in accordance with the requirements of 
the applicable local laws. A n appropriate Abbott  country representative will be utilized to understand the 
requirements for the type of insurance that will be provided for subjects, and such information will be 
incorporated into the site informed consent, as applicable.  If required, additional subject coverage or a 
clinical investigation  specific insurance will be provided by [CONTACT_1034].  
 Quality Assurance A udits and Regulatory  Inspections  
The investigator and/or delegate should contact [CONTACT_110610] a regulatory 
authority  inspection at the site. A monitor or designee will assist the investigator and/or delegate in 
preparing for the audit.  The Sponsor may perform quality assurance audits, as required.  
 
The Principal Investigator [INVESTIGATOR_423588], audits, IRB/EC review and regulatory authority inspections , as 
required. The Principal Investigator [INVESTIGATOR_423589], hospi[INVESTIGATOR_423590].  
 Repeated and S erious Non- Compliance  
In the event of repeated non- compliance or a one- time serious non- compliance, as determined by [CONTACT_429], a monitor  or designee will attempt to secure compliance by [CONTACT_294263]:  
• Visiting the investigator , 
• Contact[CONTACT_115691],  
• Contact[CONTACT_115692],  
• Retraining of the investigator . 
 
If an investigator is found to be repeatedly non- compliant with the signed agreement, the CIP or any other 
conditions of the clinical investigation , the Sponsor will either secure compliance or, at its sole discretion, 
terminate the investigator’s participation in the clinical investigation.  In case of termination, t he Sponsor 
will inform the responsible regulatory authority, as required, and ensure that the IRB/EC is notified, either 
by [CONTACT_079] [INVESTIGATOR_294219].  
13 Suspension or Premature Termination of the Clinical I nvestigation 
The Sponsor reserves the right to terminate the clinical investigation at any stage, with appropriate written 
notice to the investigator s, IRB/ ECs and relevant Regulatory authorities, if required.  
 A Principal Investigator, IRB/EC or regulatory authority may suspend or prematurely terminate participation in a clinical investigation at the invest igational sites for which they are responsible. The 
investigators will follow the requirements specified in the Clinical Trial Agreement.   If suspi[INVESTIGATOR_423591]/EC or regulatory authority, the Sponsor may suspend the clinical investigation while 
the risk is assessed. The Sponsor will terminate the clinical investigation if an unacceptable risk is 
confirmed. If the Sponsor completes an analysis of the reasons for the suspension, implements the necessary corrective actions, and decides to lift the temporary suspension, the Sponsor will inform the Principal Investigators, IRB/EC, or regulatory authority, where appropriate, of the rationale, providing 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 35 of 41 
 
them with the relevant data supporting this decision. Approval from the IRB/EC or regulatory authority, 
where appropriate, will be obtained before the clinical investigation resumes. If subjects have been 
informed of the suspension, the Principal Investigator [INVESTIGATOR_6160].  
 If the Sponsor suspends or prematurely terminates the clinical investigati on at an individual 
investigational site in the interest of safety, the Sponsor will inform all other Principal Investigators.  
 
If suspension or premature termination occurs, the Sponsor will remain responsible for providing 
resources to fulfill the obligations from the CIP and existing agreements for following up the subjects enrolled in the clinical investigation, and the Principal Investigator [INVESTIGATOR_423592]/her investigational site, if appropriat e. 
14 Clinical Investigation Conclusion  
The clinical investigation will be concluded when:  
• All sites are closed AND  
• The final report has been provided to investigators or the Sponsor has provided formal 
documentation of clinical investigation closure.  
15 Publica tion Policy  
Publications or presentations of clinical investigation methods or results will adhere to Abbott ’s publication 
policy, which is based on Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines. A cop y of the policy will be provided upon request of the investigator . 
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 36 of 41 
 
Appendix  A: CIP Revisions  
 
Procedure for CIP Amendments  
 This CIP may be amended as appropriate by [CONTACT_1034] . Rationale will be included with each amended 
version in the revision history table below . The version number and date of amendments will be 
documented.  
 The acknowledgement of the amended CIP  by [CONTACT_99835] (if applicable) and the 
Principal Investigators will be collected on the signature [CONTACT_1787] . 
 IRB/EC and  relevant R egulatory A uthorities , if applicable,  will be notified of amendments to the CIP.  
 Revision History  
Amendment 
Number  Version  Date  Rationale  Details  
Not 
Applicable  VA ddMMMyyyy  First release of CIP  NA 
 
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 37 of 41 
 
Appendix  B: Definitions  
 
Non-study Specific Definitions  
 Adverse Event (AE)  
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational m edical device under clinical investigation.  
 
This definition includes events related to the investigational medical device or the comparator.  
This definition includes events related to the procedures involved.  
 
Serious Adverse Event (SAE)  
An adverse event that led to:  
• Death  
• A serious deterioration in the health of the subject, that either resulted in:  
o A life -threatening illness or injury OR  
o A permanent impairment to a body structure or a body function OR  
o An in -patient or prolonged hospi[INVESTIGATOR_115659]  
o A medical or surgical intervention to prevent life- threatening illness or injury or permanent 
impairment to a body structure or a body function OR 
• Fetal distress, fetal death or a congenital abnormality or birth defect  
 A planned hospi[INVESTIGATOR_272] a pre- existing condition, or a procedure required by [CONTACT_423614] a serious adverse event.  
 Adverse Device Effect (ADE)  
An adverse event related to the use of an investigational medical device.  
 This definition includes adverse events resulting from  insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  
 This definition includes any event resulting from the use error or from intentional misuse of  the 
investigational medical device.  
 Serious Adverse Device Effect (SADE)  
Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.  
 Unanticipated Adverse Device Effect (UADE)  
As defined in 21 CFR §812.3, unanticipated adverse device effects (UADE) are defined as any serious adverse effect on health or safety or any life- threatening problem or death caused by, or associated with, 
a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the CIP  or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.    
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page [ADDRESS_534980] (ASADE)  
A serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome has been previously 
identified in the risk analysis report.  
 Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE)  
A serious  adverse device effect which by [CONTACT_5942], incidence, severity or outcome has not been 
identified in the current version of the risk analysis report.  
 
Device Deficiency (DD)  
A Device Deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors and inadequate labeling.  
 
Vulnerable Subject 
Vulnerable subject  is defined as individual whose willingness to volunteer in a clinical investigation could 
be unduly influenced by [CONTACT_162161], whether justified or not, of benefits associated with participation 
or of retaliatory response from senior members of a hierarchy in case of refusal to participate.  
EXAMPLE Individuals with lack of or loss of autonomy due to immaturity or through mental disability, 
persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university students, subordinate hospi[INVESTIGATOR_248925], employees of the S ponsor, members 
of the armed forces, and pers ons kept in detention.  
 
 
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 39 of 41 
 
Appendix  C: Bibliography  
 
Courtney P, Espi[INVESTIGATOR_188561] A, Mitchell B, Russo M, Muir A, Verrills  P, Davis K. (2015) Improved Pain Relief With 
Burst Spi[INVESTIGATOR_423593]: Results From a Small 
Clinical Study. Neuromodulation. Jul;18(5):361- 6.  
Crosby [INVESTIGATOR_47967], Goodman Keiser MD, Smith JR, Zeeman ME, Winkel stein BA. Stimulation parameters define 
the effectiveness of burst spi[INVESTIGATOR_423594] a rat model of neuropathic pain. Neuromodulation. 
2015 Jan;18(1):1- 8  
DeRidder D., Vanneste S., Plazier M., van der Loo E., & Menovsky T. (2010). Burst Spi[INVESTIGATOR_356425] d 
Stimulation: Toward Paresthesia- Free Pain Suppression. Neurosurgery, 66(5): 986- 990.  
DeRidder D, Plazier M, Kamerling N, Menovsky T, Vanneste S. (2013). Burst Spi[INVESTIGATOR_423595]. World Neurosurg. 2013 Jan 12. pii: S1878- 8750.   
de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D.(2014). Burst spi[INVESTIGATOR_423596]. 
Neuromodulation.17(2):152 -9.  
Taylor RS. (2006). Spi[INVESTIGATOR_423597]/failed back surgery syndrome: results of a systematic review and meta- analysis. J Pain 
Symptom Manage. Apr;31([ADDRESS_534981]):S13- 9. Review  
Vesper J, Slotty P, Poeggel -Kraemer K, Lit tges H, Agnesi F, Venkatesan L. Therapeutic Efficacy of 
BurstDRTM Microdosing in Treatment of Chronic Pain. Presented at the North American Neuromodulation 
Society Conference 2017. Las Vegas, NV, [LOCATION_003].   
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 40 of 41 
 
Appendix D: Case Report Form  
Case report forms will b e kept under a separate cover and are available upon request . 
  
 Study Document No: < SJM -CIP-XXXXX> Ver. [A]  
Study Name: [CONTACT_423615], distributed, disclosed or used without the express 
written consent of Abbott . 
 Page 41 of 41 
 
Appendix F: Informed Consent Form  
Study specific informed consent will be kept under a separate cover and is available upon request .  
 